Belatacept is a medication given by infusion that helps prevent organ rejection after transplantation. It works by suppressing the immune system in a way that is less harmful to the kidneys compared to traditional anti-rejection medications. This medication is particularly beneficial for transplant patients who are at risk of developing kidney problems.

Calcineurin inhibitors are traditional anti-rejection medications that help prevent organ rejection after transplantation. While effective at preventing rejection, they can sometimes cause kidney problems over time. In this trial, these medications are gradually reduced while belatacept is administered.

Early Graft Dysfunction – A condition that occurs shortly after heart transplantation where the newly transplanted heart doesn’t function properly. The condition typically develops within the first few hours to days after transplantation. It involves decreased heart pumping capacity and can affect how well the heart supplies blood to the body. The dysfunction may show itself through various signs of poor heart performance. Early graft dysfunction can affect both the right and left sides of the transplanted heart. The condition can vary in severity from mild to severe.

Chronic Kidney Disease (CKD) – A gradual loss of kidney function that develops over time. The kidneys become less efficient at filtering waste products from the blood. The condition progresses through several stages, with kidney function gradually declining. CKD can cause fluid retention, changes in blood pressure, and alterations in the body’s chemical balance. The disease often develops slowly over months or years.

Note: These two conditions are mentioned or implied in the trial data through the objectives and endpoints.